tetano
Editor, Senior Moderator
J Infect Dis
. 2023 Aug 7;jiad297.
doi: 10.1093/infdis/jiad297. Online ahead of print. Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database
Jin Gu Yoon[SUP] 1 [/SUP], Young-Eun Kim[SUP] 2 [/SUP], Min Joo Choi[SUP] 3 [/SUP], Won Suk Choi[SUP] 4 [/SUP], Yu Bin Seo[SUP] 5 [/SUP], Jaehun Jung[SUP] 6 [/SUP], Hak-Jun Hyun[SUP] 1 [/SUP], Hye Seong[SUP] 1 [/SUP], Eliel Nham[SUP] 1 [/SUP], Ji Yun Noh[SUP] 1 [/SUP], Joon Young Song[SUP] 1 [/SUP], Woo Joo Kim[SUP] 1 [/SUP], Dong Wook Kim[SUP] 7 [/SUP], Hee Jin Cheong[SUP] 1 [/SUP]
Affiliations
Background: Our study aimed to determine the risk of herpes zoster reactivation and COVID-19 vaccination (mRNA vaccine [BNT162b2] and adenovirus-vectored vaccine [ChAdOx1 nCoV-19]).
Methods: This retrospective study analyzed herpes zoster cases diagnosed between February 26, 2021 and June 30, 2021 and registered in the National Health Insurance Service database. A matched case-control study with a 1:3 matching ratio, and a propensity score matching (PSM) study with a 1:1 ratio of vaccinated and unvaccinated individuals were performed.
Results: In the matched case control analysis, BNT162b2 was associated with an increased risk of herpes zoster reactivation (first dose, adjusted odds ratio [aOR]: 1.11 [95% confidence interval {CI}: 1.06-1.15]; second dose, aOR: 1.17 [95% CI: 1.12-1.23]). PSM analysis revealed a statistically significant increase in risk within 18 days following any vaccination (adjusted hazard ratio [aHR]: 1.09 [95% CI: 1.02-1.16]). BNT162b2 was associated with an increased risk at 18 days post-vaccination (aHR: 1.65 [95% CI: 1.35-2.02]) and second dose (aHR: 1.10 [95% CI: 1.02-1.19]). However, the risk did not increase in both analysis of ChAdOx1 vaccination.
Conclusions: mRNA COVID-19 vaccination possibly increases the risk of herpes zoster reactivation, and thus close follow-up for herpes zoster reactivation is required.
Keywords: COVID-19 vaccination; Herpes zoster; mRNA vaccines.
. 2023 Aug 7;jiad297.
doi: 10.1093/infdis/jiad297. Online ahead of print. Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database
Jin Gu Yoon[SUP] 1 [/SUP], Young-Eun Kim[SUP] 2 [/SUP], Min Joo Choi[SUP] 3 [/SUP], Won Suk Choi[SUP] 4 [/SUP], Yu Bin Seo[SUP] 5 [/SUP], Jaehun Jung[SUP] 6 [/SUP], Hak-Jun Hyun[SUP] 1 [/SUP], Hye Seong[SUP] 1 [/SUP], Eliel Nham[SUP] 1 [/SUP], Ji Yun Noh[SUP] 1 [/SUP], Joon Young Song[SUP] 1 [/SUP], Woo Joo Kim[SUP] 1 [/SUP], Dong Wook Kim[SUP] 7 [/SUP], Hee Jin Cheong[SUP] 1 [/SUP]
Affiliations
- PMID: 37549237
- DOI: 10.1093/infdis/jiad297
Background: Our study aimed to determine the risk of herpes zoster reactivation and COVID-19 vaccination (mRNA vaccine [BNT162b2] and adenovirus-vectored vaccine [ChAdOx1 nCoV-19]).
Methods: This retrospective study analyzed herpes zoster cases diagnosed between February 26, 2021 and June 30, 2021 and registered in the National Health Insurance Service database. A matched case-control study with a 1:3 matching ratio, and a propensity score matching (PSM) study with a 1:1 ratio of vaccinated and unvaccinated individuals were performed.
Results: In the matched case control analysis, BNT162b2 was associated with an increased risk of herpes zoster reactivation (first dose, adjusted odds ratio [aOR]: 1.11 [95% confidence interval {CI}: 1.06-1.15]; second dose, aOR: 1.17 [95% CI: 1.12-1.23]). PSM analysis revealed a statistically significant increase in risk within 18 days following any vaccination (adjusted hazard ratio [aHR]: 1.09 [95% CI: 1.02-1.16]). BNT162b2 was associated with an increased risk at 18 days post-vaccination (aHR: 1.65 [95% CI: 1.35-2.02]) and second dose (aHR: 1.10 [95% CI: 1.02-1.19]). However, the risk did not increase in both analysis of ChAdOx1 vaccination.
Conclusions: mRNA COVID-19 vaccination possibly increases the risk of herpes zoster reactivation, and thus close follow-up for herpes zoster reactivation is required.
Keywords: COVID-19 vaccination; Herpes zoster; mRNA vaccines.